Optimizing Helicobacter pylori therapy through gastroenterologist education: A prospective interventional study

Figure 1 Outcome of all patients in phases I and III. ITT: Intention-to-treat; PP: Per-protocol.

Figure 2 Eradication rate of Helicobacter pylori infection in 20 physicians before and after training. A: Intention-to-treat analysis of Helicobacter pylori eradication rates in 20 physicians before and after training; B: Per-protocol analysis of Helicobacter pylori eradication rates in 20 physicians before and after training.

Figure 3 Details of eradication therapies for Helicobacter pylori infection before and after training. A: Eradication therapies for Helicobacter pylori infection before and after training; B: Acid suppressants in bismuth-containing quadruple therapy before and after training; C: Antibiotic combinations in bismuth-containing quadruple therapy before training. Others: Clarithromycin-furazolidone, furazolidone-tetracycline, clarithromycin-levofloxacin, levofloxacin-metronidazole, levofloxacin-ornidazole, amoxicillin-tetracycline, levofloxacin-furazolidone; D: Antibiotic combinations in bismuth-containing quadruple therapy after training. Others: Clarithromycin-levofloxacin, clarithromycin-metronidazole, metronidazole-tetracycline, amoxicillin-ornidazole, clarithromycin-tetracycline, clarithromycin-minocycline. AMO: Amoxicillin; CLA: Clarithromycin; LEV: Levofloxacin; MET: Metronidazole; FLU: Furazolidone; QRN: Ornidazole; ACP: Amoxicillin and clavulanate potassium; TET: Tetracycline.